- 21:00-22:00 UTC (Universal)
- 17:00-18:00 EDT (US & Canada)
- 23:00-24:00 CEST (Central Europe)
- 07:00-08:00 AEST on April 4, 2023 (Australia)
EVENT OUTLINE
- Introduction by Katherine Cashen, D.O.
- Predictors of Bleeding and Clotting in Pediatric Patients by Paul Monagle, M.D. (20 minutes)
- Anticoagulation Options for Pediatric ECMO Patients by Heidi Dalton, M.D. (20 minutes)
- Q&A with audience (15 minutes)
MODERATOR
Katie Cashen, D.O.
Duke Children's Hospital
Durham, North Carolina, United States
SPEAKERS
Paul Monagle, M.D.
Royal Children's Hospital
University of Melbourne
Melbourne, Australia
Heidi Dalton, M.D.
INOVA Fairfax Medical Center
Fairfax, Virginia, United State
- Upon completion of this activity, the learners should be able to:
- Identify common challenges for patients with cTTP, including the high disease burden during acute episodes, sub-acute manifestations, and long-term organ damage
- Assess limitations of current plasma-based standard of care therapy for patients with cTTP
- Develop prophylactic treatment strategies for cTTP to avoid sub-acute manifestations and long- term organ damage
- Associate emerging cTTP therapies with their potential clinical effects on acute episodes as well as post-acute disease stages
Accreditation Type: AMA PRA Category 1 Credit(s)™
Activity Dates: December 23, 2022— December 23, 2023
Estimated Time to Complete Activity: 60 Minutes
TARGET AUDIENCE
This educational activity is intended for physicians, advanced practice professionals (APPs), nurse practitioners, PAs who specialize in hematology, and other members of the health care team who care for patients with cTTP.
PROGRAM OVERVIEW
This self-guided, case-based educational activity reviews the high burden of disease and its treatment, the risk of relapse and long-term complications, and the emerging treatment approaches under investigation for cTTP.
The France Foundation and ISTH present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, ISTH, and the commercial supporter(s) assume no liability for the information herein.
This activity is supported by an educational grant from Takeda.
Spero R. Cataland, MD
Professor of Internal Medicine, Division of Hematology
Ohio State University
Shruti Chaturvedi, MD
Associate Professor of Medicine
Johns Hopkins
Katerina Pavenski, MD
Head, Division Transfusion Medicine
St. Michael’s Hospital
Associate Professor, Departments of Medicine and Laboratory Medicine
University of Toronto
- 16:00-17:00 UTC (Universal)
- 11:00-12:00 ET (US & Canada)
- 17:00-18:00 CET (Central Europe)
- Jan 18 | 0:00-1:00 HKT (Asia Pacific)
EVENT OUTLINE
- Introduction by Senthil Sukumar, M.D.
- Treatment of Thrombotic Microangiopathies by Spero Cataland, M.D. (20 minutes)
- Etiology-based Differential Diagnosis of TMA by Johanna Kremer Hovinga, M.D. (20 minutes)
- Q&A with audience (15 minutes)
This webinar is supported by Werfen
MODERATOR
Senthil Sukumar, M.D.
Baylor College of Medicine
Houston, Texas, United States
SPEAKERS
Johanna Kremer Hovinga, M.D.
Bern University Hospital
University of Bern
Bern, Switzerland
Spero Cataland, M.D.
Ohio State University
Columbus, Ohio, United States
- Discuss treatment considerations for persistent/chronic ITP
- Evaluate the clinical information of approved and emerging therapies for persistent/chronic ITP
- Develop individualized treatment strategies for patients with persistent/chronic ITP
TARGET AUDIENCE
The primary target audience for this content is physicians, nurse practitioners, nurses and other members of the hematology care team.
STATEMENT OF NEED
Clinicians may not know the best options for treating patients with persistent/chronic ITP who need treatment, including modifications beyond the acute ITP phase. These patients may also require individualization of treatment approach based on patient and disease characteristics.
METHOD OF PARTICIPATION/ HOW TO RECEIVE CREDIT:
- There are no fees for participating in and receiving credit for this activity
- Review the activity objectives and CME/CE information
- Complete the CME/CE activity
- Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Your CME/CE certificate will be available for download
DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
ACTIVITY STAFF DISCLOSURES
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships:
- Cindy Neunert, MD has research funding from Novartis
- Hanny Al-Samkari, MD is a consultant for Agios, Dova/Sobi, Forma, Novartis, Moderna, argenx, and Rigel and has research funding for Agios, Dova/Sobi, and Amgen
- Adam Cuker, MD is a consultant and has authoring royalties for Synergy CRO and the New York Blood Center
COMMERCIAL SUPPORT ACKNOWLEDGEMENT
This activity is supported by educational grants from Novartis, UCB, argenx, and Amgen.
FACULTY
Cindy Neunert, MD, MSCS (Chair)
Section Head, Pediatric Hematology
Columbia University Medical Center
New York, NY
Adam Cuker, MD, MS
Director, Penn Comprehensive and Hemophilia Thrombosis Program
Clinical Director, Penn Blood Disorders Center
Section Chief, Benign Hematology
Associate Professor of Medicine, University of Pennsylvania
Associate Professor of Pathology and Laboratory Medicine
Philadelphia, PA
Hanny Al-Samkari, MD
Classical Hematologist and Clinical Investigator
Co-director, Hereditary Hemorrhagic Telangiectasia Center
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
